PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Gates and Soros-backed organization buys U.K. Covid-19 testing company for $41 million

Show Me

Wireless Radiation Exposure for Children Should Be ‘Hundreds of Times Lower’ than FCC Limits, Environmental Group Says

Show Me

Harvey Weinstein pleads not guilty to sexual assault charges in LA court

Show Me

Eliminating virus risk at Tokyo Olympics is impossible, WHO leader says

Show Me

Drug Distributors and J.& J. Announce $26 Billion Deal to End Opioids Lawsuits

Show Me

Bezos says he’s creating a space industry with Elon Musk and Richard Branson

Show Me

EXCLUSIVE: House Republicans Demand Answers From Biden Over Work With Facebook To Flag ‘Disinformation’

Show Me

GOP leader rips Pelosi for rejecting Banks, Jordan on Jan 6 panel, threatens boycott

Show Me

Biden Homeland Security Announces Travel Restrictions for Americans at Border Due to COVID Variant But Southern Border Will Remain Open to Illegals

Show Me

Canada: Modern but No Longer Very Democratic or Western

Show Me

‘Unintentional Injuries’ and the Lockdown

Show Me

(FORUM) Government and Big Tech are among biggest purveyors of misinformation on Covid

Show Me

US Surgeon General Asks Big Tech to Restrict Voices That Challenge Biden Regime Narrative on Vaccinations

Show Me

Doctors for COVID Ethics: Halt Use of Pfizer COVID Vaccines in Adolescents ‘Immediately’

Show Me

Five Times More Children Committed Suicide Than Died of Covid in First Year of UK Lockdown: Study

Show Me

‘They Should Be Fired’ – Scientist Says Washington State COVID Test Info That Prompted Lockdowns Is ‘Garbage Data’

Show Me

Germany Calls on China to Allow Further Investigations Into COVID Origins

Show Me

WHO admits errors in report of COVID origins, says will correct mistakes

Show Me

China says pandemic won’t delay 2022 Winter Olympics

Show Me

IT BEGINS: The Government Is Keeping a List of Who Has Taken the COVID Vaccine and Contacting Individuals Not Vaccinated

Show Me

California Woman Is Charged in Fake Covid-19 Vaccine Card Scheme

Show Me

Dr. Fauci Has Lied To Congress & The American People About Funding Gain Of Function Viruses | Video 6 Minutes 15 Seconds

Show Me

‘We Can All Learn From China’ – Fauci-Funded Researcher Hyped CCP Vaccines and Lockdowns on Communist State Propaganda Network.

Show Me

Carroll County summer camp suspends operations after two staff members test positive for COVID

Show Me

“Perfect Storm” of Pandemic, Poverty & Jailing Ex-President Unleashes Mass Protest in South Africa

Show Me

Luntz advised Biden’s COVID-19 team

Show Me

WHO Warns South Africa to Brace For Covid-19 Surge After Riots

Show Me

False Labelling in COVID Origin Scrutiny Reminiscent of Climate Change Debate, Observers Say

Show Me

Why The Border Crisis is a Public Health Crisis

Show Me

Covid-19 UK: Alcohol deaths reach record levels after lockdown drove binge drinking at home

Show Me

If California workers must disclose COVID-19 vaccination status, why not state lawmakers?

Show Me

8 Fully Vaccinated Health Care Workers Test Positive for CCP Virus in Las Vegas: Report

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded July 21, 2021 | Video: 48 Minutes 37 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded July 21, 2021 | Video: 48 Minutes 21 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded July 21, 2021 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded July 20, 2021 | Video: 48 Minutes 49 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded July 20, 2021 | Video: 48 Minutes 21 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded July 20, 2021 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded July 19, 2021 | Video: 48 Minutes 24 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded July 19, 2021 | Video: 48 Minutes 45 Seconds

Show Me